[Effects of calcium antagonists on carbohydrate and lipid metabolism].
Preobrazhenskiĭ
D V
DV
Fomichev
V I
VI
Afanas'ev
A Ia
AIa
D000818:Animals; D002121:Calcium Channel Blockers / Q000009:adverse effects / Q000494:pharmacology*; D050260:Carbohydrate Metabolism; D002784:Cholesterol / Q000097:blood / Q000378:metabolism; D003327:Coronary Disease / Q000188:drug therapy; D003920:Diabetes Mellitus / Q000139:chemically induced; D004110:Diltiazem / Q000494:pharmacology; D005947:Glucose / Q000378:metabolism; D005951:Glucose Tolerance Test; D006706:Homeostasis; D006801:Humans; D007328:Insulin / Q000097:blood; D050356:Lipid Metabolism; D008055:Lipids / Q000097:blood; D008074:Lipoproteins / Q000097:blood / Q000378:metabolism; D008075:Lipoproteins, HDL / Q000097:blood / Q000378:metabolism; D008077:Lipoproteins, LDL / Q000097:blood / Q000378:metabolism; D009543:Nifedipine / Q000494:pharmacology; D014700:Verapamil / Q000494:pharmacology
D002121:Calcium Channel Blockers; D007328:Insulin; D008055:Lipids; D008074:Lipoproteins; D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; D002784:Cholesterol; D014700:Verapamil; D004110:Diltiazem; D009543:Nifedipine; D005947:Glucose
Vliianie antagonistov kal'tsiia na obmen uglevodov i lipidov.